Overactive bladder is a high prevalent and quality of life affecting disease. The mainstay of the medical therapy is represented by antimuscarinic drugs, but their side effects markedly affect patient compliance and prompt studies on novel investigational drugs.
Methods
A systematic literature search of peer-reviewed papers and meeting abstracts published by December 2008 was performed. PubMed databank was searched for original English articles, by using the following search terms: “overactive bladder” or “detrusor overactivity” or “urinary incontinence” and “treatment”, alone and linked to any potential molecular target or novel drug cited in the literature.
Results
Effective alternative pharmacological treatments are currently scarce, but many new promising compounds are emerging which target key molecular pathways involved in micturition control. The most promising potential therapeutic targets include central nervous system GABAergic inhibitory pathway, dopaminergic and serotoninergic systems, b-adrenoceptors and cAMP metabolism, nonadrenergic-noncholinergic mechanisms such as purinergic and neuropeptidergic systems, vanilloid receptor, bladder sensory nervous terminals, nonneuronal bladder signalling systems including urothelium and interstitial cells, prostanoids, Rho-kinase and different subtypes of potassium and calcium channels.
Conclusions
Despite the enormous amount of new biologic insight, very few novel pharmacological therapies seems to have passed the proof-of-concept clinical stage. The ultimate clinical utility of new drugs will depend on the ability to exploit tissue-specific differences and disease-related changes in molecular expression/function and to improve storage phase dysfunctions without interfering with the emptying phase. Further preclinical investigations and controlled clinical trials are urgently needed in this challenging field.
AbramsP., CardozoL., FallM., GriffithsD., RosierP., UlmstenU.. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.Neurourol Urodyn2002; 21: 167–78.
2.
NabiG., CodyJ.D., EllisG., HerbisonP., Hay-SmithJ.. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.Cochrane Database Syst Rev2006; 4: CD003781.
3.
AnderssonK.E., WienA.J.. Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence.Pharmacol Rev2004; 56: 581–631.
4.
PehrsonR., and AnderssonK.E.. Effects of tiagabine, a gamma-aminobutyric acid re-uptake inhibitor, on normal rat bladder function.J Urol2002; 167: 2241–6.
5.
SteersW.D., MeythalerJ.M., HaworthC., HerrelD., ParkT.S.. Effects of acute bolus and chronic continuous intrathecal baclofen on genitourinary dysfunction due to spinal cord pathology.J Urol1992; 148: 1849–55.
6.
MertensP., PariseM., Garcia-LarreaL., BennetonC., MilletM.F., SindouM.. Long-term clinical, electrophysiological and urodynamic effects of chronic intrathecal baclofen infusion for treatment of spinal spasticity.Acta Neurochir Suppl1995; 64: 17–25.
KontaniH., InoueT., SakaiT.. Effects of apomorphine on urinary bladder motility in anesthetized rats.Jpn J Pharmacol1990; 52: 59–67.
9.
YokoyamaO., YoshiyamaM., NamikiM., de GroatW.C.. Glutamatergic and dopaminergic contributions to rat bladder hyper-activity after cerebral artery occlusion.Am J Physiol1999; 276: R935–R942.
10.
TestaR., GuarneriL., AngelicoP., VelascoC., PoggesiE., CiliaA., and LeonardiA.. Effect of different 5-hydroxytryptamine receptor subtype antagonists on the micturition reflex in rats.BJU Int2001; 87: 256–64.
11.
KakizakiH., YoshiyamaM., KoyanagiT., and De GroatW.C.. Effects of WAY100635, a selective 5-HT1A-receptor antagonist on the micturition-reflex pathway in the rat.Am J Physiol Regul Integr Comp Physiol2001; 280: R1407–R1413.
12.
YoshiyamaM., KakizakiH., de GroatW.C.. Suppression of the micturition reflex in urethane-anesthetized rats by intracerebroventricular injection of WAY100635, a 5-HT(1A) receptor antagonist.Brain Res2003; 8: 980: 281–7.
13.
SohnU.D., KimC.Y.. Suppression of the rat micturition reflex by imipramine.J Auton Pharmacol1997; 17: 35–41.
14.
BentA.E., GousseA.E., Hendrix SlS.L., KlutkeC.G., MongaA.K., YuenC.K.. Duloxetine compared with placebo for the treatment of women with mixed urinary incontinence.Neurourol Urodyn2008; 27: 212–21.
15.
SteersW.D., HerchornS., KrederK.J., MooreK., StrohbehnK., YalcinI., BumpR.C.; Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder.BJU Int2007; 100: 337–45.
16.
ToniniM., MessoriE., FranceschettiG.P., RizziC.A., CastoldiA.F., CocciniT., and CanduraS.M.. Characterization of the 5-HT receptor potentiating neuromuscular cholinergic transmission in strips of human isolated detrusor muscle.Br J Pharmacol1994; 113: 1–2.
17.
KodamaM., and TakimotoY.. Influence of 5-hydroxytryptamine and the effect of a new serotonin receptor antagonist (sarpogrelate) on detrusor smooth muscle of streptozotocin-induced diabetes mellitus in the rat.Int J Urol2000; 7: 231–5.
18.
D'AgostinoG., CondinoA.M., GallinariP., FranceschettiG.P., and ToniniM.. Characterization of prejunctional serotonin receptors modulating (3H)acetylcholine release in the human detrusor.J Pharmacol Exp Ther2006; 316: 129–35.
19.
Hørby-PetersenJ., SchmidtP.F., MeyhoffH.H., Frimodt-MollerC., and MathiesenF.R.. The effects of a new serotonin receptor antagonist (ketanserin) on lower urinary tract function in patients with prostatism.J Urol1985; 133: 1094–8.
20.
TakimotoY., KodamaM., SugimotoS., HamadaT., FuseT., KawataN.. The effect of 5-HT 2 antagonist for urinary frequency symptom on diabetes mellitus patients.Nippon Hinyokika Gakkai Zasshi1999; 90: 731–40.
21.
DardableB., Behr-RousselD., GornyD., LebretT., BenoitG., HiebleJ.P.. Piboserod (SB 207266), a selective 5-HT4 receptor antagonist, reduces serotonin potentiation of neurally-mediated contractile responses of human detrusor muscle.World J Urol2005; 23: 147–51.
22.
WoodsM., CarsonN., NortonN.W., SheldonJ.H., and ArgentieriT.M.. Efficacy of the 3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat.J Urol2001; 166: 1142–7.
23.
HicksA., McCaffertyG.P., RiedelE., AivarN., PullenM., EvansC.. GW427353 (Solabegron), a Novel, Selective beta3-Adrenergic Receptor Agonist, Evokes Bladder Relaxation and Increases Micturition Reflex Threshold in the Dog.J Pharmacol Exp Ther2007; 323: 202–9.
24.
TakasuT., UkaiM., SatoS., MatsuiT., NagaseI., MaruyamaT.. Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-((2-hydroxy-2-phenylethyl)amino)ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.J Pharmacol Exp Ther2007; 321: 642–7.
25.
KaidohK., IgawaY., TakedaH., YamazakiY., AkahaneS., MiyataH.. Effects of selective beta2 and beta3-adrenoceptor agonists in detrusor hyperreflexia in conscious cerebral infarcted rats.J Urol2002; 168, 1247–52.
26.
LindholmP., LoseG.. Terbutaline (Bricanyl) in the treatment of female urge incontinence.Urol Int1986; 41: 158–60.
27.
GrunebergerA.. Treatment of motor urge incontinence with clenbuterol and flavoxate hydrochloride.Br J Obstetr Gynaecol1984; 91: 275–8.
28.
TrussM.C., UckertS., StiefC.G., KuczykM., and JonasU.. Cyclic nucleotide phosphodiesterae (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization.Urol Res1996; 24: 123–8.
29.
TrussM.C., UckertS., StiefC.G., ForssmannW.G., and JonasU.. Cyclic nucleotide phosphodiesterae (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro.Urol Res1996; 24: 129–34.
30.
TrussM.C., UckertS., StiefC.G., KuczykM., Schulz-KnappeP., ForssmannW-G, and JonasU.. Effects of various phosphodiesterase-inhibitors, forskolin and sodium nitroprusside on porcine detrusor muscle tonic responses to muscarinic stimulation and cyclic nucleotide levels in vitro.Neurourol Urodyn1996; 15: 59–70.
31.
LaurenzaA., SutkowskiE.M., and SeamonK.B.. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action.Trends Pharmacol Sci1989; 10: 442–7.
32.
TrussM.C., StiefC.G., UckertS., BeckerA.J., WeferJ., SchultheissD.. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.World J Urol2001; 19: 344–50.
33.
UckertS., SeemannC., StiefC.G.. Funktionelle in vitro-effekte cAMP/cGMP-modulierender pharmaka am humanen detrusormuskel.J Urol Urogynakol2002; 1: 7–14.
34.
OgerS., Behr-RousselD., GornyD., LebretT., AlexandreL., GiulianoF.. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.Eur Urol2007; 51: 772–81.
35.
FilippiS., MorelliA., SandnerP., FibbiB., MancinaR., MariniM.. Characterization and functional role of androgen-dependent PDE5 activity in the bladder.Endocrinology2007; 148: 1019–29.
36.
RuggeriMRSr. Mechanisms of disease: role of purinergic signaling in the pathophysiology of bladder dysfunction.Nat Clin Pract Urol2006; 3: 206–15.
37.
BirderL.A., de GroatW.C.. Mechanisms of disease: involvement of the urothelium in bladder dysfunction.Nat Clin Pract Urol2007; 4: 46–54.
SchroderA., TajimiM., MatsumotoH., SchroderC., BrandsM., AnderssonK.E.. Protective effect of an oral endothelin converting enzyme inhibitor on rat detrusor function after outlet obstruction.J Urol2004; 172: 1171–4.
40.
KhanM.A., ThompsonC.S., DashwoodM.R., MumtazF.H., MorganR.J., MikhailidisD.P.. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction.Curr Vasc Pharmacol2003; 1: 27–31.
41.
WestfallT.D., McCaffertyG.P., PullenM., VentreJ., EybyeM., JugusM.J.. Effect of endothelin on bladder contraction: potential role in bladder hyperactivity.Pharmacology2003; 69: 7–11.
42.
SchhepeJ.R., van den HoekJ., JunemannK.P., AlkenP.. Endothelin-A-receptor antagonist LU 302146 inhibits electrostimulation-induced bladder contractions in vivo.Neurourol Urodyn2006; 25: 468–72.
43.
OgawaT., KamoI., PflugB.R., NelsonJ.B., SekiS., IgawaY.. Differential roles of peripheral and spinal endothelin receptors in the micturition reflex in rats.J Urol2004; 172(4 Pt 1): 1533–7.
44.
NagasakaY., YokoyamaO., KomatsuK., IshiuraY., NakamuraY., NamikiM.. Effects of opioid subtypes on detrusor overactivity in rats with cerebral infarction.Int J Urol2007; 14: 226–31; discussion 232.
45.
HoltJ.D., WatsonM.J., ChangJ.P., O'NeillS.J., WeiK., PendergastW.. DPI-221 (4-((alpha-s)-alpha-((2s, 5r)-2, 5-dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N, N-diethylbenzamide): a novel nonpeptide delta receptor agonist producing increased micturition interval in normal rats.J Pharmacol Exp Ther2005; 315: 601–8.
46.
PanditaR.K., PehrsonR., ChristophT., FriderichsE., and AnderssonK.E.. Actions of tramadol on micturition in awake, freely moving rats.Br J Pharmacol2003; 139: 741–8.
47.
PehrsonR., and AnderssonK-E. Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation.J Urol2003; 170: 272–5.
48.
PehrsonR., StenmanE., and AnderssonK-E. Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction.Eur Urol2003; 44: 495–9.
49.
SafarinejadM.R., HosseiniS.Y.. Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a doubleblind, placebo-controlled, randomized study.Br J Clin Pharmacol2006; 61: 456–63.
50.
LecciA., GiulianiS., TramontanaM., CriscuoliM., and MaggiC.A.. Multiple sites of action in the inhibitory effect of nociceptin on the micturition reflex.J Urol2000; 163: 638–45.
51.
LazzeriM., CaloG., SpinelliM., GuerriniR., BenefortiP., SandriS.. Urodynamic and clinical evidence of acute inhibitory effects of intravesical nociceptin/orphanin FQ on detrusor overactivity in humans: a pilot study.J Urol2001; 166: 2237–40.
52.
LazzeriM., CaloG., SpinelliM., GuerriniR., SalvadoriS., BenefortiP.. Urodynamic effects of intravesical nociceptin/orphanin FQ in neurogenic detrusor overactivity: a randomized, placebo-controlled, doubleblind study.Urology2003; 61: 946–50.
53.
LazzeriM., CaloG., SpinelliM., MalagutiS., GuerriniR., SalvadoriS.. Daily intravesical instillation of 1 mg nociceptin/orphanin FQ for the control of neurogenic detrusor overactivity: a multicenter, placebo controlled, randomized exploratory study.J Urol2006; 176: 2098–102.
54.
IshizukaO., IgawaY., NishizawaO., and AnderssonK.E.. Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats.Neurourol Urodyn2000; 19: 101–9.
55.
SekiS., EricksonK.A., SekiM., NishizawaO., IgawaY., OgawaT.. Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation.Am J Physiol Renal Physiol2005; 288: F466–73.
56.
Abdel-GawadM., DionS.B., ElhilaliM.M.. Evidence of a peripheral role of neurokinins in detrusor hyperreflexia: a further study of selective tachykinin antagonists in chronic spinal injured rats.J Urol2001; 165: 1739–44.
57.
GreenS.A., AlonA., IanusJ., McNaughtonK.S., TozziC.A., ReissT.F.. Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence.J Urol2006; 176(6 Pt 1): 2535–40; discussion 2540.
58.
SilvaC., RibeiroM.J., and CruzF.. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input.J Urol2002; 168: 575–9.
59.
WiartL., JosephP.A., PetitH., DosqueJ.P., de SezeM., BrochetB.. The effects of capsaicin on the neurogenic hyperreflexic detrusor. A double-blind placebo-controlled study in patients with spinal cord disease. Preliminary results.Spinal Cord1998; 36: 95–99.
60.
de SezeM., GallienP., DenysP., LabatJ.J., SermentG., GriseP.. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study.Neurourol Urodyn2006; 25: 752–7.
61.
de SezeM., WiartL., de SezeM.P., SoyeurL., DospueJ.P., BlajezewskiS.. Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study.J Urol2004; 171: 251–5.
62.
SilvaC., SilvaJ., RibeiroM.J., AvelinoA., CruzF.. Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: results of a double-blind randomized placebo-controlled trial.Eur Urol2005; 48: 650–5.
KuoH.C., LIUH.T., YangW.C.. Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study.J Urol2006; 176: 641–5.
65.
AppendinoG., PetrocellisL., TrevisaniM., MinassiA., DaddarioN., MorielloA.S.. Development of the first ultra-potent “capsaicinoid” agonist at transient receptor potential vanilloid type 1 (TRPV1) channels and its therapeutic potential.J Pharmacol Exp Ther2005; 312: 561–70.
66.
ApostolidisA., PopatR., YiangouY., CockayneD., FordA.P., DavisJ.B.. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity.J Urol2005; 174: 977–82; discussion 982–3.
67.
SchurchB., de SezeM., DenysP., Chartier-KastlerE., HaabF., EveraertK.. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.J Urol2005; 174: 196–200.
68.
SahaiA., KhanM.S., DasguptaP.. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.J Urol2007; 177: 2231–6.
69.
GheiM., MarajB.H., MillerR., NathanS., O'SullivanC., FowlerC.J.. Effects of botulinumtoxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial.J Urol2005; 174: 1873–7.
70.
GiannantoniA., Di StasiS.M., StephenR.L., BiniV., CostantiniE., PorenaM.. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.J Urol2004; 172: 240–3.
71.
LipsK.S., WunschJ., ZarghooniS., BschleipferT., SchukovskiK., WeidnerV.. Acetylcholine and molecular components of its synthesis and release machinery in the urothelium.Eur Urol2007; 51: 1042–53.
72.
FaderM., GlickmanS., HaggarV., BartonR., BrooksR., Malone-LeeJ.. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial.J Urol2007; 177: 208–13; discussion 213.
73.
LagouM., DrakeM.J., Markerink-VAN IttersumM., DE VenteJ., GillespieJ.I.. Interstitial cells and phasic activity in the isolated mouse bladder.BJU Int2006; 98: 643–50.
74.
GillespieJ.I., Markerink-VAN IttersumM., DE VenteJ.. Interstitial cells and cholinergic signalling in the outer muscle layers of the guinea-pig bladder.BJU Int2006; 97: 379–85.
75.
SchroderA., NewgreenD., AnderssonK.E.. Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice.J Urol2004; 172: 1166–70.
76.
LeeT., HedlundP., NewgreenD., AnderssonK.. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction.J Urol2007; 177: 1562–7.
77.
TsukimiY., MizuyachiK., MatsumotoH., SatoM., NgB., TajimiM.. Mechanism of action by which aspirin alleviates detrusor hyperactivity in rats.J Pharmacol Sci2004; 95: 101–7.
78.
Takagi-MatsumotoH., NgB., TsukimiY., TajimiM.. Effects of NSAIDs on bladder function in normal and cystitis rats: a comparison study of aspirin, indomethacin, and ketoprofen.J Pharmacol Sci2004; 95: 458–65.
79.
ArakiT., YokoyamaT., KumonH.. Effectiveness of a nonsteroidal anti-inflammatory drug for nocturia on patients with benign prostatic hyperplasia: a prospective non-randomized study of loxoprofen sodium 60 mg once daily before sleeping.Acta Med Okayama2004; 56: 45–9.
80.
BadawiJ.K., LiH., LangbeinS., KwonS.T., KampS., BrossS.. Inhibitory effects of L- and T-type calcium antagonists on contractions of human detrusor muscle.Eur J Clin Pharmacol2006; 62: 347–54.
81.
NaglieG., RadomskiS.B., BrymerC., MathiasenK., O'RourkeK., and TomlinsonG.. A randomized, double-blind, placebo controlled crossover trial of nimodipine in older persons with detrusor instability and urge incontinence.J Urol2002; 167: 586–90.
82.
Abdel-KarimA.M., BialeckiR.A., and ElhilaliM.M.. Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats.J Urol2002; 168: 837–42.
83.
PanditaR.K., and AnderssonK.E.. Effects of intravesical administration of the K+ channel opener, ZD6169, in conscious rats with and without bladder outflow obstruction.J Urol1999; 162: 943–8.
84.
ChappleC.R., PatronevaA., RainesS.R.. Effect of an ATP-Sensitive Potassium Channel Opener in Subjects with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study (ZD0947IL/0004).Eur Urol2006; 49: 879–86.
85.
HoweB.B., HaltermanT.J., YochimC.L., DoM.L., PettingerS.J., StowR.B.. ZENECA ZD6169: a novel KATP channel opener with in vivo selectivity for urinary bladder.J Pharmacol Exp Ther1995; 274: 884–90.
86.
ChristG.J., DayN.S., DayM., SantizoC., ZhaoW., SclafaniT.. Bladder injection of “naked” hSlo/pcDNA3 ameliorates detrusor hyperactivity in obstructed rats in vivo.Am J Physiol Regul Integr Comp Physiol2001; 281: R1699–R1709.
87.
TanakaM., SasakiY., KimuraY., FukuiT., HamadaK., and UkaiY.. A novel pyrrole derivative, NS-8, suppresses rat micturition reflex by inhibiting afferent pelvic nerve activity.BJU Int2003; 92: 1031–6.
88.
PanditaR.K., RonnL.C., JensenB.F., AnderssonK.E.. Urodynamic effects of intravesical administration of the new small/intermediate conductance calcium activated potassium channel activator NS309 in freely moving, conscious rats.J Urol2006; 176: 1220–4.
89.
StrengT., ChristophT., AnderssonK.E.. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats.J Urol2004; 172(5 Pt 1): 2054–8.
90.
WibberleyA., ChenZ., HuE., HiebleJ.P., and WestfallT.D.. Expression and functional role of Rho-kinase in rat urinary bladder smooth muscle.Br J Pharmacol2003; 138: 757–66.
